Mentioned 6 times on 2 shows. Most recently heard 08/09/2026.
Every quote is verbatim and timestamped, and checked before it appears. Sponsor reads are left out. How we check
“But there's things now that give people hope. Like I don't just have to go on an anti-amyloid antibody like Lecanemab, Donanemab, which they just showed in a Cochrane review is really not making much difference. Now, maybe if you addressed the infections like Lyme and Bartonella and pulled out the mold and addressed all these other inflammatory factors,”
“as are the two other drugs subsequently approved, Lecanemab, Leqembi, and Donanemab, Kisunla. All these three drugs reduce and eventually eliminate brain levels of tau. So that when you, the person's been on the medication for some time, there's no longer any plaque in the brain.”
“And one of the things that I unfortunately have discovered is the insurance companies, especially with Lecanemab, which starts at 10 milligram dosing right away, 10 milligram per kilogram, they will not reimburse patients if we start them at a lower dose and titrate them up.”
“But unfortunately, we haven't been able to do that with Lecanemab because it just starts at 10 milligram per kilogram. Yeah. Yeah. So we've had patients, Peter, who are 4-4 patients, who've had severe ARIA on just three milligrams of Lecanemab, three milligrams per kilogram, as opposed to the 10.”
“Alternatively, also, you know, for example, one of my younger patients who's on it for prevention, she's 51 or 2, and she's developed significant ARIA-E on both sides of her brain on 3 milligrams per kilogram of Lecanemab.”
“This young woman who's got 4-4 and three Lecanemab, three milligrams of Lecanemab, who has ARIA-E, which seems fairly refractory, I treat her with steroids as you would somebody who has cerebral amyloid angiopathy with the inflammation.”